Moderna Stock Price Doubles on Melanoma Vaccine News -- WSJ
Dow Jones2026/08/19 13:43By WSJ Staff
Shares in Moderna have nearly doubled in value on news that an experimental mRNA-based vaccine it developed together with Merck succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients.
Merck stock jumped around 10%, putting it on track for a record close.
The success paves the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
August 19, 2026 09:43 ET (13:43 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Dow Jones Top Energy Headlines at 11 AM ET: Oil Rises on Persistent Hormuz Uncertainty | Energy ...
